• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Biopharma Sustainability Roundtable Releases Biopharma Investor ESG Communications Guidance Update


The Biopharma Sustainability Roundtable (BSRT) has released the Biopharma Investor ESG Communications Guidance 4.0, a resource for strategic thinking and planning of biopharma-investor ESG communications. The outcome of an ongoing dialog facilitated by the BSRT, the guidance reflects a biopharma-investor consensus on the sector’s priority ESG topics and offers recommendations on what and resources for how biopharma companies can most effectively communicate with investors about ESG strategy, governance, risks, opportunities, and performance. The Guidance 4.0 has been validated and improved through use-case experience by both biopharma and investors, and additional input from key stakeholders.

Read more about the guidance update here.

Recent Videos
Related Content